In this editorial, Timothy Sikorski (GSK; PA, USA), discusses particular considerations for developing and validating LC–MS biomarker assays using the surrogate peptide approach.
In this editorial, Robert MacNeill (Envigo) dicusses the case for the surrogate analyte approach for biomarker validation.
Find out more about ensuring the validity of biomarker measurements in this Editorial from Liam Heaney (University of Loughborough, UK).
Read time: 3:45 mins
Find out more about the immunogenicity of antibody–drug conjugates (ADCs) in this column from Corinna Fiorotti, Business Development Director at BioAgilytix (NC, USA).
Read time: 4:30 mins
In this column, Afshin Safavi differentiates between ‘assay qualification’ and ‘assay validation’ explaining current industry guidance, the translation of this guidance into the exploratory biomarker world, and how BioAgilytix (NC, USA) approaches these challenges.
In this installment of Robert MacNeill’s (Envigo) column, Robert discusses how to increase column plate count – the most obvious way!
The fourth in our monthly column series highlighting the ‘hot topics’ throughout November.
This editorial discusses the use of mass spectrometry metabolomics as a diagnositic tool for detecting metabolic syndrome. Learn more in this article from Bioanalysis.